Sign in
CompletedPhase 3

Spirulina Oral Supplement for Enhancing Host Resilience to Virus Infection

Key facts

Who runs it
University of Mississippi Medical Center
Where
Jackson, United StatesSee the site
Trial code
Status
Completed
Phase
Phase 3
People taking part
492 people enrolled
Started
1 Jul 2022
Ended
8 Dec 2025
Type of study
Interventional, 4 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Immulina TM
  • Placebo
Record updated
30 July 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 8 criteriaShow less

Who can take part

  • Ages 18-59 (study group 1) or ages 65 and above (study group 2)
  • Any chronic illness must be determined (by PI team) to be stable as evidenced by no changes in medical regimens within 30 days of enrollment
  • Ability to comprehend the specific activities required to participate in the trial for which the participant is to be enrolled

Who cannot take part

  • Active autoimmune diseases regardless of clinical stability. A history of autoimmune disease that is not considered active (i.e. no medical therapy for at least 1 year prior to enrollment) will not be excluded
  • Any acute illness or significant injury within 30 days of enrollment
  • Specific disease entities, which, in the opinion of the PI, could reasonably be assumed to have dysfunctional immune function as a component of their illness. These include HIV, AIDS, uncontrolled asthma, uncontrolled eczema, uncontrolled allergic rhinitis, uncontrolled urticaria, Rheumatoid arthritis, lupus, inflammatory bowel disease, multiple sclerosis, Type-1 diabetes mellitus, Guillain-Barr syndrome, Grave's disease, Hashimoto's thyroiditis, myasthenia gravis or vasculitis
  • History of unstable chronic illness within 30 days of enrollment
  • Unable/unwilling to commit to multiple research clinic visits which will be described in detail

Where in United States

  • University of Mississippi Medical CenterJackson, United States

About the trial

What the trial wants to find out

This randomized, double blind, placebo controlled study aims to establish the impact of the oral supplement, Immulina TM, on enhancing host resilience to the effects of viral influenza infection in humans.

The 4 groups in the trial

  • PlaceboPlacebo, for comparison

    inert capsules; 2 capsules given by mouth in the morning and 2 capsules given by mouth in the evening for 16 weeks duration.

  • Immulina TM 200 mg/dayTreatment being tested

    Immulina Dietary supplementation (200 mg per capsule); 1-200 mg capsule and 1 placebo capsule given by mouth in the morning and 2 placebo capsules given by mouth in the evening for 16 weeks duration.

    Treatment: Immulina TM

  • Immulina TM 400 mg/dayTreatment being tested

    Immulina Dietary supplementation (200 mg per capsule); 1-200 mg capsule and 1 placebo capsule given by mouth in the morning and 1-200 mg capsule and 1 placebo capsule given by mouth in the evening for 16 weeks duration.

    Treatment: Immulina TM

  • Immulina TM 800 mg/dayTreatment being tested

    Immulina Dietary supplementation (200 mg per capsule); 2-200 mg capsules given by mouth in the morning and 2-200 mg capsules given by mouth in the evening for 16 weeks duration.

    Treatment: Immulina TM

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Impact of Oral Immulina TM on Natural Killer Cell Activities and Other Biomarkers Associated With Increasing Host Immune Resilience to Upper Respiratory Viruses in Normal Human Volunteers
Record updated
30 July 2026